For research use only. Not for therapeutic Use.
Mobocertinib（Cat No.:I016825）is an oral tyrosine kinase inhibitor (TKI) specifically designed to target epidermal growth factor receptor (EGFR) exon 20 insertion mutations, a common driver of non-small cell lung cancer (NSCLC). By selectively inhibiting EGFR mutant proteins, Mobocertinib disrupts cancer cell growth and proliferation. It is particularly beneficial for patients with NSCLC harboring EGFR exon 20 insertions, a mutation typically resistant to other EGFR-targeted therapies. Mobocertinib provides a new, targeted treatment option, offering improved outcomes for patients with advanced, mutation-driven NSCLC who have limited therapeutic choices.
| Catalog Number | I016825 |
| CAS Number | 1847461-43-1 |
| Molecular Formula | C₃₂H₃₉N₇O₄ |
| Purity | 98% |
| Target | Protein Tyrosine Kinase/RTK |
| Target Protein | |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | EGFR (WT)；EGFR exon 20 insertion；HER2 |
| IUPAC Name | propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate |
| InChI | InChI=1S/C32H39N7O4/c1-9-29(40)34-24-16-25(28(42-8)17-27(24)38(6)15-14-37(4)5)35-32-33-18-22(31(41)43-20(2)3)30(36-32)23-19-39(7)26-13-11-10-12-21(23)26/h9-13,16-20H,1,14-15H2,2-8H3,(H,34,40)(H,33,35,36) |
| InChIKey | AZSRSNUQCUDCGG-UHFFFAOYSA-N |
| SMILES | CC(C)OC(=O)C1=CN=C(N=C1C2=CN(C3=CC=CC=C32)C)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC |
| Reference | [1]. Francois Gonzalvez, et al. Abstract 2644: AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models. April 16-20, 2016; New Orleans, LA.<br>[2]. Masood A, et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on BIBW 2992. Semin Oncol. 2019 Jun;46(3):271-283. |
